Genetic disorders of the oral cavity: A comprehensive review of clinical, pathological, and molecular aspects

INTRODUCTION

Dermatology, the branch of medicine focused on skin diseases, has gained prominence not only due to primary skin conditions but also because the skin often reflects deeper systemic or visceral diseases. Dermatologists understand that many skin disorders can also involve mucous membranes throughout the body, including those in the oral cavity. It is equally essential for dentists to recognize that certain dermatoses present with oral mucosal lesions, sometimes even preceding skin involvement. This makes dentists pivotal in the early diagnosis of dermatologic diseases before cutaneous signs appear. A significant group of such disorders is known as genodermatoses – a collection of inherited skin diseases. Some of these conditions are particularly marked by abnormal keratinization, referred to as genokeratoses. However, not all keratinization disorders are of genetic origin.^[1] “Genodermatoses” (from geno meaning genetic and dermatosis meaning skin disease) encompass a variety of rare inherited conditions that manifest on the skin and often in the oral cavity, referred to as oral genodermatoses. The identification of genes responsible for abnormalities in epidermal structures has shed light on the intricate molecular pathways involved in their development and function. The oral cavity often reflects underlying systemic conditions. Given the common embryological origin of the skin and oral tissues from the ectoderm, many cutaneous disorders present oral manifestations, impacting both soft and hard tissues. Effective management of genodermatoses calls for close interdisciplinary collaboration between dentists and dermatologists. Moreover, medications used to treat skin disorders can influence dental care. Dental management in these patients includes maintaining oral hygiene, improving esthetics, and providing orthodontic and prosthetic rehabilitation as needed.^[2]

Dyskeratosis congenita (DC) is a rare inherited bone marrow failure syndrome characterized by a classical triad of nail dystrophy, reticular skin pigmentation, and oral leukoplakia. It is associated with severe complications, including aplastic anemia, myelodysplastic syndrome, leukemia, and various epithelial cancers. A hallmark of the disorder is significantly shortened telomeres, affecting high-turnover tissues and leading to features of premature aging.^[3] DC affects approximately 1 in 1 million individuals, with a male predominance. Onset typically occurs between 5 and 12 years of age, though clinical presentation and severity vary widely.^[4] Inheritance patterns may be X-linked, autosomal dominant, or autosomal recessive, and about 70% of patients harbor identifiable germline mutations. Mutations that impair telomerase function lead to defective cell renewal, particularly in hematopoietic and epithelial tissues.^[5] Bone marrow failure, occurring in approximately 85% of cases, is the leading cause of mortality. Affected individuals are at a significantly increased risk for malignancies, particularly squamous cell carcinoma of the oral cavity and other mucosal sites, often arising within preexisting leukoplakic lesions. Oral leukoplakia typically involves the buccal mucosa, tongue, and oropharynx [Figure 1]. These lesions may develop a verrucous texture or ulcerate, with a high potential for malignant transformation. Additional oral features may include increased dental caries, enamel hypoplasia, early tooth loss, and periodontal disease.^[6] Oral leukoplakia exhibits hyperkeratosis, acanthosis, and occasionally, epithelial dysplasia. Diagnosis is clinical, based on the classic triad and associated systemic features.^[1] Genetic testing can identify causative mutations and confirm the diagnosis.^[7] Management strategies for bone marrow failure include the use of androgens. Immunosuppressive therapy is generally ineffective. Allogeneic hematopoietic stem cell transplantation remains the only curative treatment option, though it carries substantial risk. Lifelong surveillance is crucial due to the elevated cancer risk, especially for oral squamous cell carcinoma. Comprehensive multidisciplinary care and genetic counseling are essential components of long-term management.^[8]

Close

Figure 1:

Dyskeratosis congenita. (a) Thin homogeneous leukoplakia on the right buccal mucosa (red arrow), (b) hyperkeratosis with mucosal atrophy on the dorsal surface of the tongue.

Export to PPT

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant polyposis disorder characterized by multiple hamartomatous polyps throughout the gastrointestinal (GI) tract and distinctive mucocutaneous pigmentation, particularly around the lips, buccal mucosa, and extremities.^[9] The syndrome was initially observed by an English physician and illustrated by Hutchinson J,^[10] The term PJS was introduced in 1954 by Bruwer et al.,^[11] who integrated the earlier work of Peutz JL,^[12] who documented familial GI polyposis with mucosal pigmentation, and Jeghers H et al., who delineated it as a distinct clinicopathologic entity.^[13] PJS has an estimated incidence of 1 in 50,000 to 1 in 200,000 live births and affects both males and females equally. The cumulative risk of cancer in affected individuals increases significantly with age, reaching approximately 1% by age 20, 19% by age 40, 63% by age 60, and 81% by age 70.^[14] Mutations lead to dysfunctional cell cycle regulation, contributing to the formation of polyps and tumorigenesis.^[1] Freckle-like melanotic macules usually emerge in early childhood and are typically found around the mouth, nose, eyes, anus, genitalia, and extremities [Figure 2]. Unlike typical freckles, these macules do not darken with sun exposure and may fade over time. Hamartomatous polyps, occur in the jejunum and ileum, and can lead to complications such as intussusception, bowel obstruction, and GI bleeding. Oral pigmentation is present in over 90% of cases and often serves as an early diagnostic clue. These lesions appear as 1–4 mm brown to bluish-gray macules affecting the vermilion border of the lips, labial and buccal mucosa, and the tongue. The epithelium covering these polyps is usually benign, though pseudoinvasion may be noted. Biopsies of pigmented lesions reveal mild acanthosis, elongation of rete ridges, and increased melanin in basal keratinocytes. There is no increase in melanocyte count, but melanocytes show elongated dendritic processes and a tendency to retain pigment.^[15] Diagnosis of PJS is confirmed through histopathologic identification of hamartomatous polyps. The differential diagnosis includes other pigmentary disorders such as Carney complex, which is also associated with lentigines and endocrine tumors.^[16] Management of PJS emphasizes early detection and intervention. Oncologic surveillance is tailored based on individual risk and includes screening for breast, pancreatic, gynecologic, and testicular malignancies. Although mucocutaneous pigmentation is typically benign and requires no intervention, cosmetic treatment options such as cryotherapy, dermabrasion, or Q-switched lasers may be considered based on patient preference.^[17]

Close

Figure 2:

Peutz-Jeghers syndrome. (a) Multiple dark brown lentigines and freckle like lesions on the vermillion border of the lip, (b) multiple dark brown lentigines on the buccal mucosa.

Export to PPT

Papillon-Lefevre syndrome (PLS) is a rare autosomal recessive genodermatosis that presents primarily with palmoplantar hyperkeratosis and severe, early-onset periodontitis involving both primary and permanent dentitions. Additional features may include hyperhidrosis, arachnodactyly, intracranial calcifications, heightened susceptibility to infections, and, in some cases, intellectual disability.^[18] The syndrome was first described in 1924 by two French physicians, Papillon and Lefèvre.^[19-21] Clinical signs typically emerge between 2 and 3 years of age, coinciding with the eruption of the primary teeth.^[22] Mutations result in deficient neutrophil and lymphocyte activation, leading to a dysregulated immune response to microbial pathogens and impaired epithelial barrier function. These deficits are responsible for the characteristic aggressive periodontal destruction and skin manifestations of the syndrome.^[15] Cutaneous features begin to manifest between 6 months and 4 years of age, with the development of hyperkeratotic lesions on the palms and soles. The lesions may present as white, yellow, brown, or red patches and plaques, which can fissure, crust, or mimic psoriatic lesions. Other dermatologic signs may include follicular hyperkeratosis, nail dystrophy, and excessive sweating. Orally, the syndrome is notable for severe periodontitis that usually begins shortly after the eruption of primary teeth. Although the primary teeth erupt normally and have typical morphology, they quickly become mobile and painful due to marked gingival inflammation, deep periodontal pockets, pus discharge, and rapid alveolar bone destruction [Figure 3]. Fetid oral odor and regional lymphadenopathy may also be present. Most children lose their primary dentition by the age of 4 or 5 years. This is followed by a transient period of gingival health, which deteriorates again with the eruption of permanent teeth, leading to total tooth loss by adolescence (typically between 13 and 15 years). Radiographic imaging reveals the classic appearance of “floating teeth” due to severe bone resorption. Unerupted teeth may appear morphologically normal or may have abnormal positioning and root development.^[23] Histopathologic examination of gingival tissue in PLS shows hyperkeratosis, acanthosis, and hypergranulosis. There is often a dense inflammatory infiltrate in periodontal pockets, including exocytosis of neutrophils. Radiographically, both localized and generalized bone loss patterns are observed. Unerupted teeth may exhibit incomplete root formation or altered positioning.^[15] Differential diagnoses include several conditions with overlapping features. Acrodynia (mercury poisoning) is distinguished by systemic symptoms such as erythrocyanosis, insomnia, tachycardia, and muscle pain. Other genodermatoses, such as Howel–Evans syndrome, Greither syndrome, and keratosis punctata, share features of palmoplantar keratosis but do not exhibit periodontal destruction. Management of PLS requires a coordinated, multidisciplinary approach involving dermatologists, pediatricians, and dental specialists.^[24]

Close

Figure 3:

Papillon-Lefèvre syndrome. (a) Marked red inflamed and swollen gingivae, (b) missing permanent teeth in upper and lower arch.

Export to PPT

White sponge nevus (WSN) is a rare, autosomal dominant genodermatosis that is characterized by a defect in mucosal keratinization. It was first described by Hyde in 1909 and later termed by Cannon in 1935. WSN has high penetrance with variable expressivity, which means that the severity and extent of the condition can differ significantly among individuals, even within the same family. The most common site of involvement is the buccal mucosa, although other areas, such as the labial mucosa, alveolar ridge, floor of the mouth, ventral tongue, and soft palate, can also be affected.^[15] The keratin proteins form intermediate filaments in the spinous layer of mucosal epithelium, and mutations in these genes result in fragile keratin networks.^[25] The clinical features of WSN are characterized by bilateral, diffuse, and symmetrical lesions. The affected mucosa appears thickened, folded or corrugated, soft, and white, with a spongy texture [Figure 4]. The lesions are typically asymptomatic and persistent, although occasionally, they may exhibit ragged white areas that can be removed by gentle rubbing without bleeding. Extraoral involvement, such as in the nasal, esophageal, or anogenital mucosa, is rare.^[1] Microscopically, WSN is characterized by prominent hyperparakeratosis, marked acanthosis, and perinuclear cytoplasmic clearing in the spinous layer cells. These histological features can sometimes resemble conditions such as leukoedema or hereditary benign intraepithelial dyskeratosis (HBID). Cytologic smears stained with Papanicolaou stain may help reveal eosinophilic perinuclear condensation, which can aid in diagnosis [Figure 4].^[15] If there is uncertainty, a biopsy may be recommended. While WSN is typically asymptomatic, patients may seek treatment due to concerns about the altered mucosal texture or for cosmetic reasons. Some patients have reported benefit from low-dose, long-term systemic antibiotics. There is no standard therapy for WSN, and the focus of management is on maintaining good oral hygiene to prevent secondary infections. Diagnosis is primarily based on clinical history, examination, and histopathology.^[25]

Close

Figure 4:

White sponge nevus. (a) The affected mucosa is characterized by a thickened, folded, or corrugated appearance, with a soft, white coloration and a spongy texture, (b) shows vacuolation of the cytoplasm in the spinous layer cells, along with perinuclear condensation of keratin tonofilaments (black arrow).

Export to PPT

Neurofibromatosis type 1 (NF-1), also known as von Recklinghausen’s disease, is a common autosomal dominant neurocutaneous disorder. It is characterized by a variety of manifestations, including skin pigmentation anomalies, neural tumors, and skeletal abnormalities. Some individuals may experience learning disabilities, attention deficits, seizures, and skeletal deformities.^[26] The condition was first described in the 13^th century, but it was Friedrich Daniel von Recklinghausen’s seminal work in 1882 that established NF-1 as a distinct disorder.^[27] Later, in 1953, Crowe et al.,^[28] expanded on the clinical spectrum of NF-1, and in 1982, Riccardi proposed a classification system for neurofibromatosis, some elements of which are still used today.^[29] The condition is typically diagnosed in early childhood, with signs usually appearing by age 10. NF-1 does not show any significant gender or racial predilection.^[30] Etiologically, NF-1 is caused by mutations in the NF-1 gene located on chromosome 17. Loss of neurofibromin leads to unchecked RAS activation, promoting tumor growth, pigmentary changes, and skeletal anomalies.^[31] The clinical features of NF-1 can vary widely, but most individuals experience a benign progression. Café-au-lait macules, which are light brown patches, are often the earliest sign, appearing as ≥6 lesions that measure ≥5 mm in prepubertal children or ≥15 mm in postpubertal individuals. Skeletal abnormalities include scoliosis, pseudoarthrosis (particularly of the tibia), and sphenoid wing dysplasia. Patients with NF-1 also have an increased risk of malignancies, including optic gliomas, astrocytomas, schwannomas, Wilms’ tumor, leukemia, rhabdomyosarcoma, and others.^[32] Oral manifestations of NF-1 are highly variable, affecting between 4% and 92% of patients. The most common oral finding is enlargement of the fungiform papillae, seen in approximately 50% of cases [Figure 5]. Radiographic features include enlarged mandibular foramen or canal as well as cortical bone changes such as coronoid notch widening and alterations in bone density.^[15] Histopathologically, neurofibromas show unencapsulated spindle cell proliferation with mucinous stroma and numerous mast cells, including Schwann, perineural, and fibroblastic cells [Figure 5]. Caféau-lait spots are characterized by increased melanin in the basal cell layer and melanosis. The diagnosis of NF-1 is clinical, and it requires two or more of the following National Institute of Health (NIH) criteria: ≥6 café-au-lait macules, ≥2 neurofibromas, or 1 plexiform neurofibroma; axillary or inguinal freckling, optic glioma; ≥2 Lisch nodules; distinctive osseous lesion (e.g., sphenoid dysplasia); and a first-degree relative with NF-1. Management of NF-1 is symptomatic and multidisciplinary. There is no curative treatment, but surgical excision or CO₂ laser treatment can be used for disfiguring neurofibromas. Regular monitoring for malignancies, seizures, and skeletal issues is essential, with annual follow-up using magnetic resonance imaging (MRI) in infancy and childhood. Genetic counseling is critical as offspring have a 50% chance of inheriting the condition. Patients and their families must be informed about the potential complications and variable expressivity of the disorder.^[33]

Close

Figure 5:

Neurofibromatosis type 1. (a) Unilateral enlargement of tongue, (b) histology of neurofibroma demonstrating spindle cell proliferation, with a mixture of Schwann cells, fibroblasts, and nerve fibers embedded in a collagenous stroma (Hematoxylin and eosin stain, 20x).

Export to PPT

Ehlers-Danlos syndrome (EDS) is a group of clinically and genetically heterogeneous heritable connective tissue disorders. EDS is characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. The condition was first documented by Edward Ehlers in 1901, a Danish dermatologist, and Henri-Alexandre Danlos in 1908, a French physician. EDS is divided into six major subtypes, incorporating molecular and clinical criteria. Advances in molecular genetics and clinical phenotyping have since expanded the phenotypic spectrum, and the Online Mendelian Inheritance in Man database is now used for ongoing classification updates.^[34] The combined prevalence of all EDS types is approximately 1 in 5,000 individuals. The classical type accounts for about 10% of cases, with a prevalence of 1 in 20,000–40,000. The vascular type, which is rare, has a prevalence of 1 in 100,000.^[35] There is no strict gender or racial predilection, although females are more commonly diagnosed with the hypermobile form. Patients with EDS often exhibit distinctive facial features, such as sparse hair, hypertelorism, a wide nasal bridge, epicanthic folds, protruding ears, and frontal bossing. Joint hypermobility is a hallmark of classical EDS, with both large and small joints being affected. Common problems include subluxation or dislocation of the shoulder, knees, and TMJ. Mucosal fragility, caused by alterations in types I, III, and V collagen, is a hallmark across all EDS subtypes. Common oral findings include mucosal bruising and red pinpoint lesions due to blood extravasation, regenerative patches, with pale-bordered gray/white areas indicating bruises that heal poorly. In Type VIII EDS, periodontal manifestations are prominent and include early-onset, aggressive periodontitis, premature loss of deciduous and permanent teeth, gingival recession, and tooth mobility. Impaired oral hygiene due to bleeding, mucosal fragility, and restricted hand movement can further complicate oral care. Dental anomalies may also be present, including hypodontia, abnormal pulp shapes, pulp calcifications, crenulated incisors, dilacerated or stunted roots, supernumerary or congenitally missing teeth, a flat dentinoenamel junction, a high-arched palate, absence of labial and lingual frenula, and a positive Gorlin’s sign (the ability to touch the nose tip with the tongue). Histopathology is generally non-specific or non-diagnostic. A definitive diagnosis is made based on a combination of clinical features, radiological findings, and confirmatory laboratory investigations. Management depends on the specific subtype of EDS. Vascular EDS is associated with significant morbidity and a high risk of sudden death from arterial rupture due to weakened vessel walls. Accurate diagnosis is crucial for both prognostic counseling and genetic counseling, particularly considering the variation in inheritance patterns among subtypes.^[36-38]

Epidermolysis bullosa (EB) refers to a heterogeneous group of hereditary disorders characterized by extreme fragility of the skin and mucous membranes, resulting in blister and ulcer formation in response to minimal trauma. The clinical complexity of EB is heightened by its multisystem involvement, which extends beyond the skin to affect various extracutaneous sites, including skin adnexa, teeth, and the epithelial linings of the GI tract, urinary tract, and respiratory system.^[39] The incidence of EB appears to be unaffected by race or ethnicity. The classification of EB has evolved significantly over the years. The first classification, proposed by Pearson in 1962^[40] using electron microscopy, categorized EB into three major types based on the ultrastructural level of skin cleavage. A consensus meeting in Vienna in 2007 updated the classification to include newly described clinical variants such as Kindler syndrome, laryngo–onycho–cutaneous syndrome, lethal acantholytic EB simplex (EBS), migratory circinate EBS, and plakophilin deficiency EB.^[41] Over 1000 mutations across more than 10 structural genes in the basement membrane zone (BMZ) contribute to phenotypic variability.^[42] Oral involvement is extensive, with bullae and feeding difficulties, enamel, and dentin defects. Histology shows cleavage within the lamina lucida and resembles recessive DEB histologically [Figure 6]. DEB includes dominant and recessive forms. Dominant DEB presents with variable onset, blisters that heal with scarring, milia, and dystrophic nails. Oral milia are seen in about 20% of cases. Histologically, cleavage occurs beneath the BMZ, characterized by fragmentation of the BMZ and the absence of elastic fibers. Recessive DEB is severe, with widespread blistering from birth, positive Nikolsky’s sign, and scarring leading to mitten deformities. Oral involvement is common, with blistering, painful erosions, ankyloglossia, vestibular obliteration, enamel hypoplasia, and missing teeth. Histologically, cleavage occurs sub-lamina densa, and the BMZ is located on the blister roof, characterized by increased and fragmented elastic fibers.^[43]

Close

Figure 6:

Epidermolysis bullosa. (a) Clear blister at the level of the dermoepidermal junction with no inflammatory infiltrate (red arrow), (b) reduced depth of the labial vestibule caused by repeated mucosal tearing and healing with scarring.

Export to PPT

Ectodermal dysplasia (ED) refers to a group of genetic disorders that typically present with a triad of hypohidrosis (reduced sweating), hypotrichosis (scanty hair), and hypodontia (missing or malformed teeth). ED is caused by disrupted interactions between the ectoderm and mesenchyme during embryogenesis, which impairs the development of skin, hair, teeth, nails, and sweat glands.^[44] Hypohidrotic ED (Christ–Siemens–Touraine syndrome) is the most common form of ED, typically caused by mutations in the ectodysplasin A (EDA) gene (Xq12-13), which encodes ectodysplasin. This protein is crucial for ectodermal development, and mutations in it can result in clinical features such as hypotrichosis, hypohidrosis, hypodontia, peg-shaped teeth, nail anomalies, and heat intolerance due to reduced sweating [Figure 7].^[45] Hypohidrotic ectodermal dysplasia (HED) results from defects in the ectodysplasin signaling pathway, essential for the development of teeth, hair follicles, and sweat glands. The prevalence of X-linked HED is estimated at 21.9/100,000, with dental anomalies present in approximately 79% of cases.^[46] Diagnosis is most commonly made between the ages of 11 and 18. Females typically present milder, patchy features, often along Blaschko’s lines. Patients with HED often present with smooth, dry, and thin skin; periorbital/perioral hyperpigmentation; sparse hair (scalp, axillary, and pubic); absent eyebrows/eyelashes; nail anomalies (spoon-shaped nails may be seen); and systemic issues such as lacrimal gland dysfunction, asthma, eczema, and heat intolerance. Dental anomalies can range from anodontia to peg-shaped or conical teeth, with delayed eruption of both primary and permanent dentition. Hypoplastic alveolar ridges and full lips are characteristic, and approximately 80% of female carriers exhibit dental abnormalities. Histopathology typically reveals reduced or absent sweat glands and pilosebaceous units. The differential diagnosis includes other forms of HED, ED with immunodeficiency or deafness, and milder cases resembling Sjögren syndrome. Diagnosis is clinical, based on the characteristic features such as heat intolerance, hair and dental anomalies, and absent sweat glands, with supporting evidence from neonatal skin peeling, eczema, frequent infections, and dermatoglyphic or lacrimal secretion patterns. Multidisciplinary management is essential for addressing systemic issues such as asthma, infections, and salivary deficiency.^[47]

Close

Figure 7:

Ectodermal dysplasia. (a) Conical teeth and hypodontia in hypohidrotic ectodermal dysplasia, (b) thickened and shortened nails, (c) hypotrichosis in hidrotic ectodermal dysplasia.

Export to PPT

Gardner syndrome (GS), first described by Gardner in 1953, is an autosomal dominant disorder characterized by intestinal polyposis, multiple osteomas, and various soft tissue tumors. Additional features include supernumerary teeth, dental anomalies, fibrous dysplasia, desmoid tumors, epidermoid cysts, and increased cancer susceptibility.^[48] By 1962, the syndrome was expanded to include dental anomalies and sebaceous cysts.^[49] The condition can present from early childhood to late adulthood, with colonic polyps typically emerging in the second decade of life. It is inherited in an autosomal dominant manner, with a 50% risk of transmission. There is no racial predilection, but individuals with Gardner syndrome have a high risk of colorectal cancer and other malignancies associated with familial adenomatous polyposis (FAP), including those affecting the small bowel, thyroid, liver, and central nervous system (CNS). Gardner syndrome results from mutations in the adenomatous polyposis coli (APC) gene, located on chromosome 5q21. The APC gene is a tumor suppressor gene that regulates cell growth through the β-catenin signaling. Additional mutations, such as those in the RAS, TP53, and DCC genes, as well as epigenetic changes, contribute to tumorigenesis.^[50] Cutaneous lesions are common and include epidermoid cysts (present in 50– 65% of cases), fibromas, desmoid tumors, and other benign skin tumors. Oral manifestations occur in approximately 30% of patients and include dental anomalies such as supernumerary or unerupted teeth, odontomas, and tooth agenesis or malformation. These dental changes may precede other symptoms, such as the development of intestinal polyps, which can help in early diagnosis. Histologically, osteomas in Gardner syndrome are typically of the compact type and are indistinguishable from solitary osteomas. Diagnosis is based on clinical features and is confirmed by testing for mutations in the APC gene. Diagnostic criteria include the presence of at least 100 colorectal polyps or a family history of FAP, as well as osteomas, epidermoid cysts, and desmoid tumors. Diagnostic tools, such as colonoscopy, imaging (e.g., X-rays of the jaw and skull), and retinal examination, are used to support the diagnosis. Management of Gardner syndrome is focused on vigilant screening and preventive surgery, as the condition is incurable. Screenings include annual thyroid examinations and imaging for desmoid tumors and hepatoblastoma. Medical therapy may include non-steroidal anti-inflammatory drugs (e.g., sulindac), anti-estrogens, or chemotherapy for desmoid tumors. Osteomas and cysts may be surgically removed for functional or cosmetic reasons.^[51]

Cowden syndrome (CS) is a rare autosomal dominant disorder marked by hamartomatous growths from all three germ layers and an increased risk of cancers, most notably breast, thyroid, and endometrial. It shows high penetrance and variable expressivity. It is typically diagnosed between the ages of 13 and 65 and is more common in females.^[52] It affects multiple systems, including the thyroid, breast, CNS, genitourinary, GI, skin, and skeletal systems. Clinical features of CS include skin manifestations such as multiple facial trichilemmomas, acral and palmoplantar keratoses, hemangiomas, neuromas, and lipomas.^[53] Thyroid involvement is seen in 75% of cases, with conditions such as goiter, thyroiditis, adenomas, and thyroid cancers. Breast fibrocystic disease is common, with breast cancer risk rising to 77% by age 70. Approximately 50% of patients have GI polyps, increasing their risk of colorectal cancer. Other features include macrocephaly (80%), endometrial cancer (5–10%), ovarian cysts, neurodevelopmental delay, immune dysfunction, and a 6% prevalence of melanoma. Oral manifestations include pink or white papules (1–3 mm), often forming papillomatous plaques across the palate, gingiva, and labial mucosa. Additional features include scrotal tongue, gingival hypertrophy, macrocheilitis, hypopharyngeal polyps, uvula hypoplasia, caries, periodontitis, and oral squamous cell carcinomas.^[54] Histopathology of skin lesions shows trichilemmomas with epithelial hyperplasia, papillomatosis, parakeratosis, and acanthosis, and some may contain HPV DNA. Oral lesions are characterized by non-specific fibroepithelial hyperplasia.^[55] Diagnosis is primarily clinical, and diagnosed when any of the following are present: pathognomonic lesions such as six or more facial papules (with at least three being trichilemmomas), facial papules combined with oral mucosal papillomatosis, oral papillomatosis with acral keratoses, or six or more palmoplantar keratoses; alternatively, a diagnosis can be made with two major criteria (one of which must be macrocephaly), one major and three minor criteria, or four minor criteria. Management of CS focuses on early detection of malignancies, patient education, and genetic counseling. Regular cancer surveillance, as per NCCN guidelines, is crucial and involves monitoring the breast, thyroid, endometrium, and colon, depending on individual risk factors.^[56,57]

CONCLUSION

Oral genodermatoses, though rare, present significant diagnostic and management challenges due to their diverse clinical manifestations and genetic underpinnings. A comprehensive understanding of these conditions is essential for early diagnosis, interdisciplinary care, and genetic counseling. Advances in molecular genetics and precision medicine hold promise for improving patient outcomes through targeted therapies and personalized management strategies. Continued research and clinical awareness are imperative to bridge existing gaps and enhance the quality of life for affected individuals.